BioNexus Expands AI Integration and Renewable Energy Ventures

Introduction

BioNexus Gene Lab Corp (Nasdaq: BGLC) is a biotechnology company based in Kuala Lumpur, founded in 2017. It specializes in blood-based dynamic genomic screening (BGS), analyzing circulating RNA to assess an individual’s predisposition to diseases before symptoms emerge. Its flagship test evaluates risk for eight common cancers, two inflammatory diseases, and osteoarthritis. The company’s co-founder was the late Professor Emeritus Dato’ Dr. Liew Choong-Chin, a prominent figure in cardiovascular genome research at Brigham and Women’s Hospital, Harvard Medical School.

Corporate Structure and Experience

BioNexus operates through two primary segments: MRNA Scientific Sdn. Bhd., which develops non-invasive liquid biopsy tests, and Chemrex, a specialty chemical supply business serving industrial and medical markets across Southeast Asia. The corporate headquarters is in Kuala Lumpur. According to its LinkedIn profile, the company employs between 11 and 50 staff, many of whom hold advanced degrees in molecular biology, genomics, and related fields. Under CEO Sam Tan’s leadership, BioNexus has strengthened its board with independent directors and established an internal audit function.

Genomic Screening by CDC

Recent Developments and News

On April 19, 2024, MRNA Scientific agreed to invest RM 1.2 million (approximately USD 250,000) in Ascension Innovation Sdn. Bhd. (AISB) to integrate AI-driven predictive analytics into AISB’s aiCMS health-management platform.
On September 25, 2024, BioNexus subsidiary MRNA Scientific signed a three-year teaming agreement with Protech Builders Sdn. Bhd., committing up to RM 1,000,000 jointly to develop biogas plants that convert plantation wastewater into renewable energy.
On March 8, 2025, BioNexus announced a strategic partnership with ML Tech, an AI-driven wealth management platform, to implement an Ethereum-focused treasury strategy aimed at optimizing returns on its digital asset holdings.
On April 3, 2025, the company completed a reverse stock split, adjusting its CUSIP number to meet Nasdaq listing standards.
On April 30, 2025, and June 23, 2025, BioNexus filed current reports (Form 8-K) indicating changes in its board and executive officers, further reinforcing its corporate governance structure.

Financial and Strategic Analysis

As of July 2, 2025, BGLC shares are trading at USD 6.13, down 44.97% from the prior period, with a daily volume of 172,293 shares. According to the most recent quarterly data:

• Net income for the latest quarter was a loss of USD 623,330, compared to a loss of USD 348,320 in the preceding quarter.
• EBITDA stood at –USD 2.13 million, representing an EBITDA margin of –18.96%.
• Market capitalization is approximately USD 20.0 million.

Strategically, BioNexus maintains a dual-focus model. Its MRNA Scientific arm targets the growing liquid biopsy market through RNA-based diagnostics, while its Chemrex division leverages chemical supply contracts to fund R&D initiatives. The company’s digital health investments—such as the AISB partnership and Ethereum treasury strategy—demonstrate an aim to integrate AI and blockchain technologies into both its core operations and financial management.

Market Position and Industry Context

The global digital health market was valued at USD 240.9 billion in 2023, with AI in healthcare projected to reach USD 187.7 billion by 2030. BioNexus’s BGS test differentiates itself by combining FDA-approved reagents with dynamic RNA analysis, positioning the company within the precision medicine segment. Its entry into the biogas sector via the Protech agreement signals diversification into renewable energy, aligning with sustainability trends. The company’s Nasdaq listing under the ticker BGLC provides access to U.S. capital markets, supporting future fundraising and potential M&A activities.

tl;dr

• On March 8, 2025, BioNexus Gene Lab Corp. partnered with ML Tech to launch an Ethereum-based treasury strategy.
• The company completed a reverse stock split on April 3, 2025, and updated its board and executive team through 8-K filings on April 30 and June 23, 2025.
• As of July 2, 2025, BGLC shares trade at USD 6.13, reflecting a 44.97% decline; the latest quarterly loss was USD 623,330.
• Future outlook centers on scaling RNA-based diagnostics, integrating AI-driven platforms in healthcare, and pursuing sustainable energy projects.